Navigation Links
ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
Date:3/14/2010

ATLANTA, Georgia, March 14, 2010 /PRNewswire/ -- Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower). This is achieved by adding fenofibrate to simvastatin. Only 20 of these patients need to be treated for 5 years to prevent one cardiovascular event.

To view the Multimedia News Release, please click: http://multivu.prnewswire.com/mnr/r3i/42622/

In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial, published on-line in the New England Journal of Medicine,(1) the group with atherogenic dyslipidemia had 70 percent more cardiovascular events (cardiovascular death, heart attacks and strokes) than patients without. In fact, the risk associated with atherogenic dyslipidemia was comparable to that in people with previous cardiovascular disease (17.3 percent versus 18.1 percent).


'/>"/>
SOURCE Residual Risk Reduction initiative (R3i)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
2. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
7. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
8. As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
9. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
10. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ore. , July 22, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today announced that ... before the open of U.S. financial markets on July ... Semler will host a conference call at 11 a.m. ...
(Date:7/22/2014)... 2014 Holomic is expanding its ... of its fluorescent immunoassay reader, the HRDR-300, at ... in Chicago, July 28-31, 2014. Available in both ... HRDR-300 is a highly sensitive, low-cost fluorescent reader ... lateral flow immunoassays with high sensitivity and accuracy. ...
(Date:7/22/2014)... Dr. Williams says, “Bush has joined the constantly ... greatest health care system in the world is too ... trying to serve the public. Unfortunately, Bush has also ... enormous system that none of them can first describe ... of Open Letters ( http://is.gd/wdU2CM ) provides a critique ...
(Date:7/21/2014)... College of Arts and Sciences has received a ... nanoparticles. , Mathew M. Maye, associate professor of ... from the National Science Foundation (NSF). The award ... nanostructures, the results of which may impact gas ... , Maye,s approach is novel, in that ...
Breaking Biology Technology:Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2
... , , ROCKVILLE, Md., July 21 ... appointment of John J. Trizzino as Senior Vice President, International ... Trizzino will report directly to Dr. Rahul Singhvi, Novavax,s President ... managing the company,s international alliances with pharmaceutical companies and all ...
... ... is pleased the U.S. Environmental Protection Agency will allow farmers the ability to improve upon ... for SmartStax, an insect-protection and weed control platform in corn, to 5 percent in the ... ...
... , , NEWARK, N.J., July 21 ... a specialty chemical technology based Life Science Company announced ... protocol testing, BioNeutral,s Ygiene(TM) Hospital Grade Antimicrobial passed the ... all 5.4 million spores of Clostridium difficile ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2EPA Refuge Determination Positive for the Environment 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3
(Date:7/22/2014)... team from the National Institute of Standards and ... demonstrated a dramatically improved technique for analyzing biological ... "signatures." The new NIST technique is an advanced ... but one that delivers signals that are 10,000 ... and 100 times stronger than obtained from comparable ...
(Date:7/22/2014)... reputation as disease causing agents, some viruses can ... to shape the world we live in today, ... Academy of Microbiology. , "Viruses participate in essential ... the planet, from contributing to biogeochemical cycles, shaping ... states Marilyn Roossinck of Pennsylvania State University, a ...
(Date:7/22/2014)... promise for treating damaged organs and tissues, but with ... their effectiveness. New methods are being developed and tested ... after transplantation, as described in a Review article in ... Mary Ann Liebert, Inc., publishers. The article is available ... website . , In the article ,Preconditioning ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... Researchers speaking in the first plenary session of the ... (IAS 2011) have today offered insights into current and ... developments over the past two years are beginning ... policy. The presentations reflect the breadth of expertise ...
... trailing a long length of rope behind you is not ... to manoeuvre, and can get tangled up or stuck on ... apart during cell division. The chromosomes are pulled by their ... Just like climbers carry their rope coiled up, cells make ...
... PHILADELPHIA The use of trastuzumab, chemotherapy and ... improved survival from the time central nervous system metastases ... researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now ... chemotherapy, even if cancer spreads to the brain." ...
Cached Biology News:Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 2Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 3Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 4Keeping it together 2Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients 2